177lu-psma-617,olaparib
novartis,merck,astrazeneca
['luparp', 'prostate', '177lu,psma,617', 'psma-617 ', 'olaparib']
luparp: phase 1 trial of 177lu-psma-617 and olaparib in patients with metastatic castration resistant prostate cancer. no g4 aes or dlt psa50 response % 66 orr is 78% promising but need to see comparative study! #asco23 
On the road! Medical Oncologist & Prof @AnkaraUni | GU cancer expert  🔬| Diversity & Equity 📢 Advocate 💫  🌍 #Oncology #GenitourinaryCancer